Srebf1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The SREBF1 gene (commonly known as SREBP1) encodes sterol regulatory element-binding protein 1, a critical transcription factor that regulates lipid metabolism and cellular energy homeostasis[1]. SREBP1 serves as the master regulator of fatty acid and triglyceride synthesis, controlling genes involved in lipogenesis, cholesterol biosynthesis, and lipid droplet formation. Beyond its well-established role in metabolic diseases, SREBP1 has emerged as an important player in neurodegenerative disorders, where lipid dysregulation contributes to disease pathogenesis[2].
SREBP1 belongs to the SREBP family of transcription factors:
| Isoform | Gene | Function | Tissue Expression |
|---|---|---|---|
| SREBP1a | SREBF1 | Strong activator, full-length | Widely expressed |
| SREBP1c | SREBF1 | Insulin-regulated isoform | Liver, adipose, brain |
The SREBP1 gene produces multiple transcripts through alternative splicing:
SREBP1 contains several functional domains:
SREBP1 controls the expression of genes involved in[3]:
Fatty Acid Synthesis:
Triglyceride Synthesis:
Cholesterol Synthesis:
Beyond lipid synthesis, SREBP1 regulates:
SREBP1 is expressed throughout the brain:
SREBP1 dysregulation is prominent in AD[4]:
Lipid Metabolism Abnormalities:
Amyloid Processing:
Therapeutic Implications:
SREBP1 involvement in PD[5]:
SREBP1 dysfunction in HD:
SREBP1 hyperactivity contributes to:
| Approach | Compound | Mechanism | Status |
|---|---|---|---|
| SREBP1 inhibitor | Fatostatin | Prevents cleavage | Preclinical |
| SREBP1 inhibitor | Betulin | Blocks maturation | Preclinical |
| Statins | Simvastatin | Indirect reduction | Approved |
| Farnesoid X receptor agonists | Obeticholic acid | FXR-SREBP1 axis | Approved for PBC |
The study of Srebf1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125-1131. DOI:10.1172/JCI15593 ↩︎
Brown MS, Radhakrishnan A, Goldstein JL. Retrospective on Cholesterol Homeostasis: The Central Role of SREBP. Cold Spring Harb Perspect Biol. 2018;10(12):a033290. DOI:10.1101/cshperspect.a033290 ↩︎
Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710-730. DOI:10.1038/nrendo.2017.91 ↩︎
Liu Y, Chen L, Gong J. SREBP1 in Alzheimer's Disease: A Potential Therapeutic Target. Front Aging Neurosci. 2022;14:856785. DOI:10.3389/fnagi.2022.856785 ↩︎
Van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2019;18(9):856-867. DOI:10.1016/S1474-4422(1930009-6 ↩︎